DataMeds AI launches up to $7,045,403 at-the-market common stock offering
DataMeds AI, Inc. entered into an at-the-market sales agreement with Dawson James Securities, Inc. to offer and sell from time to time up to $7,045,403 of common stock. Assuming sales at the November 16, 2026 closing price of $0.642 per share, the program could issue up to 10,974,147 shares and raise shares outstanding from 5,724,857 to up to 16,699,004, with net proceeds intended for debt repayment, working capital and other general corporate purposes.
Key takeaways
Offering size: The prospectus supplement covers an at-the-market offering of common stock with an aggregate offering price of up to $7,045,403.
Sales agent: Dawson James Securities, Inc. will act as sales agent or principal and will receive a 3.0% cash commission on aggregate gross proceeds, with certain expenses reimbursable.
Potential share issuance: At the assumed $0.642 per share price, up to 10,974,147 shares may be sold, taking shares outstanding from 5,724,857 to up to 16,699,004.
Use of proceeds: Net proceeds, if any, are intended for debt repayment, working capital and other general corporate purposes, with pending proceeds invested in short-term, investment-grade instruments and government securities.
Dilution: On a fully subscribed basis at $0.642 per share, pro forma as adjusted net tangible book value would be $(22.7) million, or $(1.36) per share, with immediate dilution of $2.00 per share to new investors.
No minimum offering: The number of shares sold, gross proceeds, commissions and net proceeds are not determinable because no minimum offering amount is required, and either party may terminate the Sales Agreement on ten days' prior notice.
Other dilution sources: Share counts exclude 9,442,355 warrant shares with a weighted average exercise price of $7.31, 21,687,403 shares issuable on conversion of outstanding convertible promissory notes, and 920,191 shares reserved under the Amended and Restated 2023 Equity Incentive Plan.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.